Back to results
US 2019/0367555 A1Published application
Prodrugs of the selective progesterone receptor modulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one
AssigneeBayer Pharma Aktiengesellschaft
InventorsHans-Christian MILITZER, Antje ROTTMANN, Andrea WAGENFELD, Horst IRLBACHER
Life of this patent
Estimating the term…
Abstract
This invention concerns Selective Progesterone Receptor Modulators (SPRM) in a prodrug form as well as their application in therapy. (3α, 11β,17β)-1 1-[4-(methylsulfonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-diene-3,17-diol (Compound 1) is one of the invention prodrugs.
Claims22
A prodrug of a Selective Progesterone Receptor Modulator (SPRM) wherein the SPRM is selected from (11β,17β)-17-Hydroxy-11-[4-(methyl sulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.